Radioligand therapy is evolving rapidly. With new targets like HER2 and FAP coming into focus, and promising data emerging beyond PSMA and SSTR2, there’s real momentum building in the field. But to fully unlock the potential of these therapies across Europe, and to integrate RLT as the next pillar of oncology treatment, we need more than scientific innovation. We need collaboration and harmonisation across the entire development journey. 
The 7th Targeted Radiopharmaceuticals Summit Europe is here to make that happen.
This is the go-to meeting for anyone working to bring the next generation of targeted radiopharmaceuticals to patients, whether you’re involved in early discovery, clinical development, manufacturing, or regulatory affairs. Designed with input from leaders across the RLT space, this year’s summit is packed with practical insights, honest conversations, and real-world solutions.